Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBT: 2019-2025

Historic EBT for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $67.5 million.

  • Harmony Biosciences Holdings' EBT rose 8.56% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.5 million, marking a year-over-year increase of 31.44%. This contributed to the annual value of $191.8 million for FY2024, which is 10.62% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported EBT of $67.5 million as of Q3 2025, which was up 35.97% from $49.6 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' EBT's 5-year high stood at $67.5 million during Q3 2025, with a 5-year trough of -$10.5 million in Q3 2021.
  • Over the past 3 years, Harmony Biosciences Holdings' median EBT value was $51.8 million (recorded in 2024), while the average stood at $49.0 million.
  • Data for Harmony Biosciences Holdings' EBT shows a peak YoY increase of 59,688.89% (in 2021) and a maximum YoY decrease of 651.18% (in 2021) over the last 5 years.
  • Over the past 5 years, Harmony Biosciences Holdings' EBT (Quarterly) stood at $24.5 million in 2021, then surged by 80.20% to $44.1 million in 2022, then decreased by 10.01% to $39.7 million in 2023, then spiked by 41.49% to $56.2 million in 2024, then rose by 8.56% to $67.5 million in 2025.
  • Its last three reported values are $67.5 million in Q3 2025, $49.6 million for Q2 2025, and $57.2 million during Q1 2025.